1 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow BIVV001 (Low Dose): new trials by email Literature Review of BIVV001 (Low Dose) trials Research Report on BIVV001 (Low Dose)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A) Advate (Low Dose), Advate (High Dose), BIVV001 (Low Dose) - Hemophilia A | Phase 1 / Phase 2 | Completed | Bioverativ, a Sanofi company | 16 | 2017-08-28 | 2022-04-19 |
Hemophilia A (1)
Bioverativ, a Sanofi company (1)
Japan (1) · United States (1)